Physician profile
Adrian Zhubi
NPI 1861634990
$3,733.55
in general payments reported to CMS, 2019-2025
24 companies · $979 in 2025
The $979 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $320 · 2021: $489 · 2022: $701 · 2023: $567 · 2024: $544 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.56 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $360.09 | 2024-2025 | Cobenfy |
| Allergan, INC. | $244.10 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.26 | 2021-2025 | Caplyta |
| Corium, LLC | $217.91 | 2022-2025 | Azstarys |
| Tris Pharma INC | $193.68 | 2022-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $164.78 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $119.47 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $110.91 | 2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $106.39 | 2020-2025 | Rexulti |
| Alkermes, INC. | $106.31 | 2022-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $96.45 | 2021-2025 | Fanapt |
| Eisai INC. | $92.20 | 2020-2022 | |
| Indivior INC. | $87.95 | 2024-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $70.12 | 2022-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $69.61 | 2021-2023 | Cotempla Xr-Odt |
| Adlon Therapeutics L.P. | $53.74 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $46.87 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $45.98 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $32.35 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.37 | 2022 | |
| Noven Therapeutics, LLC | $21.59 | 2025 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $19.13 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.73 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Zhubi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.